Press release
1 March 2022
Cellular Goods PLC
('Cellular Goods' or 'the Company')
Launch of Rejuvenating Cannabinoid Face Serum
Cellular Goods (LSE: CBX), a UK-based wellness company that provides premium consumer products formulated with lab-made cannabinoids, is pleased to announce the launch today of its Rejuvenating Cannabinoid Face Serum as part of its 'Look Better' (skincare) range.
Cellular Goods' Cannabinoid Face Serum is the UK's first cannabigerol (CBG)-powered serum, which works to prevent the signs of aging caused by UV-light exposure and inflammation. The product contains ultra-pure, biosynthetic CBG and its development has been informed by the findings of the Company's recent white paper, which revealed that CBG has anti-inflammatory and antioxidant properties, giving it immense potential for age-prevention skincare solutions.
The serum will allow the Company to meet demand for products that have demonstrated effectiveness in addressing the signs of aging without causing harmful side effects, such as irritation and photosensitivity, that industry standard active ingredients retinol and Vitamin C can produce.
Cellular Goods' face serum has gone through an extensive testing process and is fully validated for marketing and labelling as suitable for sensitive skin, dermatologically tested and dermatologist approved.
The product, which has a retail price of £99, is available on the Amazon Marketplace and the Company's ecommerce platform, found at www.cellular-goods.com.
The product uses lab-made CBG, does not require the cultivation of the cannabis sativa plant and contains 0% THC, the psychoactive component of cannabis sativa.
Anna Chokina, CEO of Cellular Goods, commented: "We are thrilled to be revolutionising the wellness industry with the launch of the UK's first CBG-powered skincare serum. CBG has demonstrated antioxidant and anti-inflammatory properties that qualify it as an ingredient of the future with immense potential for skincare solutions designed to prevent the signs of aging.
"Developing science-backed products is at the heart of what we do, and this has enabled us to offer customers a skincare product that can deliver the same or better results as traditional age prevention products without the uncomfortable side effects associated with some popular active ingredients. As a sensitive skin consumer, I am excited about the prospect of giving more people access to the age preventing solutions of the future, such as our exclusive Rejuvenating Serum. We look forward to continuing to use science to develop truly innovative products that offer tangible benefits to our consumers. The launch of our serum strengthens Cellular's existing product line-up and expands our consumer offering, which coupled with the visibility generated by our increased sales channels, will help drive sales."
For further information please contact:
| Cellular Goods | |
| Anna Chokina Chief Executive Neil Thapar Investor Relations | via Tancredi +44 207 887 7633
+44 787 645 5323 |
| Tennyson Securities | |
| Corporate Broker Peter Krens |
+44 207 186 9030 |
| Novum Securities | |
| Corporate Broker Colin Rowbury Jon Belliss |
+44 207 399 9427 |
| Tancredi Intelligent Communication | |
| Media Relations Helen Humphrey Gabriela Amaya Garcia Edward Daly Charlie Hobbs |
+44 744 922 6720 +44 791 503 5294 +44 786 143 0057 +44 789 755 7112 |
About Cellular Goods PLC:
Cellular Goods is a UK-based wellness company that provides premium products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid-powered wellness products. The initial focus is on three product verticals: Function Better, Feel Better and Look Better. These three verticals encompass Cellular Goods' premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website. The Company's shares are listed on the main market of the London Stock Exchange. www.cellular-goods.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
